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Abstract  
 
Introduction:   Various bleeding risk prediction schemes, such as the HAS-BLED, ATRIA and 
ORBIT scores have been proposed in patients with atrial fibrillation (AF).  We compared the 
relative predictive values of these bleeding risk scores for clinically relevant bleeding, as well 
as the relationship of ATRIA and ORBIT scores to the quality of anticoagulation control on 
warfarin, as reflected by time in therapeutic range (TTR). 
Methods: A post-hoc ancillary analysis of ‘clinically relevant bleeding’ and ‘major bleeding’ 
events amongst 2293 patients on warfarin therapy in the AMADEUS trial. 
Results: Only HAS-BLED was significantly predictive for clinically relevant bleeding, and all 3 
risk scores were predictive for major bleeding.  The predictive performance of HAS-BLED 
was modest, as reflected by c-indexes of 0.59 (p<0.001) and 0.65 (p<0.002), for clinically 
relevant bleeding and major bleeding, respectively. The HAS-BLED score performed better 
than ATRIA (P=0.002) or ORBIT (P=0.001) in predicting any clinically relevant bleeding.  Only 
the HAS-BLED score was significantly associated with the risk for both bleeding outcomes on 
Cox regression analysis (any clinically relevant bleeding; hazard ratio [HR] 1.85, 95%CI 1.43-
2.40, p<0.001, and major bleeding; HR 2.40, 95%CI 1.28-4.52, p=0.007).   
There were strong inverse correlations of ATRIA and ORBIT scores to TTR as a continuous 
variable (‘low risk’ ATRIA, r= -0.96; P=0.003; ORBIT, r= -0.96; p=0.003).  Improvement in the 
predictive performance for both ATRIA and ORBIT scores  for any clinically relevant bleeding 
was achieved by adding TTR to both scores, with significant differences in c-indexes 
(p=0.001 and p=0.002, respectively), NRI and IDI (both p<0.001).   
Conclusion:  All three bleeding risk prediction scores demonstrated modest predictive ability 
for bleeding outcomes, although the HAS-BLED score performed better than either the 
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ATRIA or ORBIT scores.  Significant improvements in both ATRIA and ORBIT score prediction 
performances were achieved by adding TTR to both scores.   
 
 
Key words   bleeding, HAS-BLED, ORBIT, ATRIA, risk assessment, anticoagulation 
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Introduction 
 
Various bleeding risk scores have been derived in general populations undergoing 
anticoagulation, and validated in patients with atrial fibrillation (AF); for example, the HAS-
BLED score (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or 
predisposition, Labile international normalized Ratio, Elderly, Drugs/alcohol)
1
; and the ATRIA 
(Anticoagulation and Risk Factors in Atrial Fibrillation) score.
2
   More recently, a new 
bleeding prediction score, the ORBIT (Outcomes Registry for Better Informed Treatment) 
score, was developed from a large observational cohort of atrial fibrillation patients 
3
, and 
validated in the ROCKET-AF trial cohort 
4
.   The ORBIT score was proposed as a simple 
bedside score, to be used with any oral anticoagulant (Vitamin K Antagonist (VKA, eg. 
warfarin) or non-VKA oral anticoagulant (NOAC)).   In patients taking VKA, both the ATRIA 
and ORBIT scores do not consider quality of anticoagulation control, as reflected by the time 
in therapeutic range (TTR) whilst the HAS-BLED score includes this within the L criterion 
(‘labile INR’).  This is despite TTR being strongly correlated to the risk of serious bleeding in 
patients taking VKA
5, 6
. 
 
In this study, we tested the hypothesis that the HAS-BLED score would perform at least as 
well as the ATRIA and new ORBIT scores in predicting the principal trial safety outcome of 
any clinically relevant bleeding, in addition to the secondary endpoint of major bleeding.  
Second, we hypothesised that the addition of TTR to the ATRIA and ORBIT scores would 
identify additional patients at high risk of clinically relevant bleeding.   We tested these 
hypothesis in a post-hoc analysis of warfarin-treated patients from the AMADEUS trial 
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(Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial 
Fibrillation) trial 
7
.     
 
 
Methods 
 
The design and results of the AMADEUS trial have previously been described. 7, 8  In brief, 
this was a multicentre, randomized, open-label non-inferiority study with blinded 
assessment of outcome that compared fixed-dose idraparinux with conventional 
anticoagulation with dose-adjusted oral VKA for the prevention of thromboembolism in 
patients with atrial fibrillation and an indication for long-term anticoagulation.  Eligible 
patients had ECG-documented nonvalvular atrial fibrillation and an indication for long-term 
anticoagulation, based on the presence of at least one of the following risk factors: previous 
ischemic stroke, transient ischemic attack (TIA) or systemic embolism, hypertension 
requiring drug treatment, left ventricular dysfunction, age >75 years, or age 65-75 with 
either diabetes mellitus or symptomatic coronary artery disease.   Exclusion criteria included 
the inability to provide consent, contraindication or other requirement for anticoagulation, 
calculated creatinine clearance of <10 mL/min, breastfeeding, pregnancy and recent or 
anticipated invasive procedures with potential for uncontrolled bleeding. There was blinded 
assessment of trial outcomes, and for this ancillary analysis, outcomes were analysed for the 
warfarin arm of the trial only, as the development of idraparinux has been discontinued and 
thus, less relevant for our clinical practice. 
 
Bleeding Risk Scores Assessment 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 7 
The acronym HAS-BLED represents each of the bleeding risk factors and assigns 1 point for 
the presence of each of the following bleeding risk factors: Hypertension (uncontrolled 
systolic blood pressure >160 mm Hg), Abnormal renal and/or liver function, previous Stroke, 
Bleeding history or predisposition, Labile INR (international normalized ratio; only applies to 
a VKA user – otherwise not applicable for a non-VKA user), Elderly (age ≥65 years), and 
concomitant Drugs and/or alcohol excess. In the present analysis, the variable “labile 
international normalized ratio (INR)” was defined for a TTR<60%.  For this study, we used 
each patient’s first 5 INR measurements following study entry to calculate the TTR.  A HAS-
BLED score of 0-2 was categorized as “low risk”, while HAS-BLED ≥3 was categorized as “high 
risk”. 
 
The ATRIA score was developed from the Anticoagulation and Risk Factors in Atrial 
Fibrillation (ATRIA)
2
 study cohort and calculated using the following: anaemia (haemoglobin 
<13 g/dl in men and <12 g/dl in women) (3 points), severe renal disease (estimated 
glomerular filtration rate <30 ml/min/1.73m
2
) (3points), age ≥75 years (2 points), prior 
bleeding and hypertension.   An ATRIA score of 0-3 is defined as “low risk”, while a score=4 
was “Intermediate risk” and a score ≥5 was “high risk”. 
 
The ORBIT score was developed from the “Outcomes registry for better informed treatment 
of atrial fibrillation” (ORBIT-AF) registry,
3
  and calculated as follows: 1 point each for age 
older than 74, insufficient kidney function (estimated glomerular filtration rate < 60 
ml/min/1.73m
2
) and treatment with any antiplatelet, while 2 points were assigned to a 
positive clinical history for bleeding and the presence of anaemia or abnormal haemoglobin 
(<13 mg/dL for males and <12 mg/dL for females). An ORBIT score 0-2 was “low risk”, while 
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“intermediate risk” was a score of 3 and a score ≥4 was “high risk”.   In the present study, 
none of the patients had a history of alcohol abuse or prior major bleeding at study entry, as 
these were criteria for exclusion from the AMADEUS trial, and therefore those components 
were categorised as 0. 
 
Definitions of endpoints 
This post-hoc analysis of the AMADEUS trial used pooled data from the VKA arm on an 
intention to treat basis.  The principal adjudicated safety outcome of the present analysis 
was ‘any clinically relevant bleeding’, which was defined as major bleeding and/or non-
major clinically relevant bleeding. The latter was defined as overt bleeding that did not 
satisfy the criteria for major bleeding but that met pre-defined criteria and included 
repetitive epistaxis for more than 5 min at least twice in 24 h, haematuria (spontaneous or 
lasting more than 24 h), hematemesis, and subcutaneous haematomas of more than 25 cm² 
if spontaneous, or more than 100 cm² if after trauma. Major bleeding was defined as 
bleeding that was fatal, intracranial or affecting another critical anatomical site, overt 
bleeding with a drop of haemoglobin ≥20 g/L or requiring transfusion of two or more units 
of erythrocytes.  
 
All suspected outcome events were adjudicated by the original AMADEUS central 
adjudication committee, who were blinded to treatment assignment. 
 
Statistical analysis 
All continuous variables were tested for normality with the Shapiro-Wilk test. Variables with 
normal distribution were expressed as means and standard deviations (SD). Non-parametric 
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variables were expressed as median and interquartile range (IQR). Categorical variables, 
expressed as counts and percentages, were analysed by chi-squared test. Bleeding 
outcomes by each bleeding risk scheme were calculated as the overall rate of adverse 
events per 100 patient-years.  
 
A Cox regression analysis was performed to investigate the association between three 
bleeding risk schemes and bleeding outcomes, such as any clinically relevant bleeding and 
major bleeding. Pearson correlations and regression analyses were performed between TTR 
and any clinically relevant bleeding, in relation to the ATRIA and ORBIT scores.  
 
Receiver operating characteristic (ROC) curves were compiled for the three risk scores, 
according to bleeding outcomes, in order to evaluate their predictive ability using the area 
under the curve method (AUC, a measure of their c-index). Their respective AUCs were then 
compared according to De Long, De Long and Clarke-Pearson method.
9
   We also tested the 
predictive ability of the ATRIA and ORBIT scores with and without the addition of TTR, by 
comparing AUCs as well as calculating the net reclassification improvement (NRI) and 
integrated discrimination improvement (IDI) using PredicABEL, an R package for the 
assessment of risk prediction prediction model.
10
  
11
  A two-sided p value <0.05 was 
considered statistically significant. All analyses were performed using SPSS v. 22.0 (IBM, NY, 
USA), MedCalc v. 15.6 (MedCalc Software, Belgium) and R statistic for Windows 3.2.2. 
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Results 
 
The AMADEUS study randomized 2293 patients to warfarin (65% male; median age: 71 
years, IQR 64-77). In total, 251 (11%) patients experienced at least 1 clinically relevant 
bleeding event, whilst 39 (1.7%) had at least 1 episode of major bleeding.  Demographic and 
clinical characteristics of the AMADEUS population are summarized in Table 1. Bleeding 
event rates in the study population, as stratified by the three bleeding scores, are shown in 
Figure 1. 
 
Predictive performance of HAS-BLED, ATRIA and ORBIT 
Median HAS-BLED score in the study cohort was 2 (IQR, interquartile range: 1-2), whilst the 
median ATRIA score was 1 (IQR: 1-3) and median ORBIT score was 1 (IQR: 0-1).   Only HAS-
BLED was significantly predictive for clinically relevant bleeding, and all 3 scores were 
predictive for major bleeding.  The predictive performance of HAS-BLED was modest, as 
reflected by c-indexes of 0.59 (p<0.001) and 0.65 (p<0.002), for clinically relevant bleeding 
and major bleeding, respectively.  Corresponding c-indexes for the ATRIA score were 0.50 
(p=0.50, non-significant) and 0.61 (p=0.02), respectively. For the ORBIT score, c-indexes 
were 0.52 (p=0.30, non-significant) and 0.61 (p=0.02), respectively (see Figure 2).     
 
In a Cox regression analysis, a HAS-BLED score ≥3 was associated with a 1.85-fold greater 
hazard for any clinically relevant bleeding (p<0.001) and a 2.4-fold greater hazard for major 
bleeding (p=0.007).  On a similar Cox regression analysis, an ATRIA score ≥4 was not 
significantly associated with any clinically relevant bleeding (p=0.54) but was associated 
with a 2.4-fold greater hazard of major bleeding (p=0.03).  An ORBIT score ≥3 was not 
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significantly associated with any clinically relevant bleeding (p=0.36) but was associated 
with a 2.9-fold greater hazard of major bleeding (p=0.01) (see Table 2). 
 
Comparison of bleeding scores  
The HAS-BLED score performed significantly better than ATRIA (p=0.002) or ORBIT (p=0.001) 
in predicting any clinically relevant bleeding, as reflected by comparison of AUC analyses 
(Table 3). The AUCs for ATRIA vs ORBIT were similar (p=0.66).   For major bleeding, AUC 
differences for the 3 scores did not reach statistical significance. 
  
Impact of TTR on the ORBIT and ATRIA scores 
Any clinically relevant bleeding in relation to tertiles of Time to Therapeutic Range (TTR) and 
TTR as a continuous variable, by ORBIT and ATRIA scores are shown in Figure 3.   
There was a high absolute event rate for clinically relevant bleeding amongst patients with 
poor anticoagulation control (TTR<50%; ie. >15 per 100 person-years) even among those 
categorised as ‘low risk’ using these 2 scores, whereas there was a strong negative 
correlation to TTR as a continuous variable (ATRIA, Pearson r= -0.96; P=0.003; ORBIT, r= -
0.96; p=0.003).  This correlation was also significant for the ATRIA intermediate/high score 
group (r= - 0.85; p=0.03), with a non-significant trend with the ORBIT intermediate/high 
score group (r= - 0.77; p=0.07).  
 
The improvements in prediction performance by adding TTR to the ATRIA or ORBIT scores 
are shown in Table 4.   For the ATRIA score, adding TTR would result in a significant 
improvement in AUC (p=0.001), with a NRI of 0.26 (p<0.001) and an IDI of 0.0066 (p<0.001), 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 12
compared to ATRIA score without TTR.  For the ORBIT score, the AUC difference was also 
significant (p=0.002), with NRI of 0.26 (p<0.001) and IDI of 0.0065 (p<0.001).   
 
 
Discussion 
 
In this study, we compared the ability of the HAS-BLED, ATRIA and ORBIT scores to predict 
bleeding events in a clinical trial cohort of atrial fibrillation patients taking warfarin, and also 
examined the relationship of these scores to TTR. We show that the HAS-BLED score 
performed better than the ATRIA and ORBIT scores, especially in predicting clinically 
relevant bleeding events.  Second, there was a strong correlation of TTR with clinically 
relevant bleeding events in patients assessed by the TRIA and ORBIT, even amongst those 
categorised as ‘low risk’.  Third, we show clear improvements in prediction performance by 
adding TTR to both the ATRIA and ORBIT scores. 
 
Despite the increasing use of NOACs, the VKAs are still very widely used worldwide and 
increasing attention has been directed to the importance of good anticoagulation control, as 
reflected by the TTR.  The HAS-BLED score accounts for ‘labile INRs’ (the ‘L’ criterion – which 
is only applicable for a VKA-taking patient) by giving it one point, but the ATRIA and ORBIT 
scores do not recognise the importance of this criterion when calculating bleeding risk.    
This is despite evidence that labile INRs (whether defined by poor TTRs or other measures 
indicative of poor anticoagulation control 
6, 12, 13
) are a strong predictor of excess bleeding 
risk.  Indeed, we demonstrate that the risk of any clinically relevant bleeding (and major 
bleeding) decreases overall with better anticoagulation control.  Importantly, there was high 
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absolute event rate for clinically relevant bleeding amongst the patients with poor 
anticoagulation control (TTR<50%; >15 per 100 person-years) even amongst those 
categorised as ‘low risk’ using the ATRIA and ORBIT scores, as well as a strong negative 
correlation to TTR, when analysed as a continuous variable with these 2 bleeding scores. 
Significant improvements in score predictive performance were gained by adding TTR to 
both ATRIA and ORBIT scores for clinically relevant bleeding, as reflected by a significant 
difference in AUC, NRI and IDI.  Thus, both these scores may perform suboptimally in 
identifying serious bleeding risk in a patient on VKA, unless they are re-calibrated taking 
labile INRs (or TTRs) into consideration.  The HAS-BLED score already considers ‘labile INR’ 
as one of its criteria, which is applicable only for a VKA user (whilst the L criterion is not 
applicable if a NOAC is used). 
 
Since its original description in the EuroHeart survey, the HAS-BLED score has been validated 
in both large real-world and clinical trial populations, and recently reviewed in a 
comprehensive European consensus document.
14
  Prior direct comparisons with other 
bleeding prediction scores, such as HEMORR2HAGES and ATRIA, have shown that the HAS-
BLED score is as good as – and possibly better – than other scores in the evaluation of 
bleeding risk. 
8, 15
   The more recently proposed ORBIT score was derived from a large 
industry-sponsored registry, and validated in the ROCKET-AF trial cohort, with the claim to 
be simple and applicable to all anticoagulants, whether VKA or NOAC. 
3
   
 
As shown in the present study, all three bleeding scores showed modest discriminatory 
capacity for bleeding outcomes, as reflected by c-indexes <0.70, although HAS-BLED was the 
only score predictive of both clinically relevant and major bleeding.   For major bleeding 
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events, all three scores demonstrated similar predictive ability, but with c-indexes <0.70.  
These c-indexes (approximately 0.6) are perhaps typical of clinical risk scores based on 
clinical features, including those used for stroke risk prediction such as the CHADS2 and 
CHA2DS2-VASc scores.   Rather then undue focus on statistical significance in predicting the 
high risk patients who develop an event, the clinical applicability of bleeding risk scores 
requires attention to the reversible risk factors for bleeding
16
, especially since both stroke 
and bleeding risks are closely associated. 
 
For example, the HAS-BLED score is used to ‘flag up’ the patient potentially at high risk of 
bleeding, who may require more careful review and followup – and to direct attention to 
the potentially reversible bleeding risk factors, such as uncontrolled hypertension (the H 
criterion), labile INRs (the L criterion) and concomitant drugs (aspirin, NSAIDs) or excess 
alcohol (the D criterion) that the responsible clinician can address.  Indeed, this is the 
approach recommended in current guidelines
12, 17
.    Of note, the ORBIT score does not 
include uncontrolled hypertension, labile INRs, alcohol excess or concomitant NSAIDs within 
its criteria
16
. 
 
A high HAS-BLED score is not a reason to withhold OAC, as such patients derive an even 
greater net clinical benefit when balancing stroke prevention against the potential for 
increased serious bleeding
18, 19
, an approach also recommended in guidelines
12, 17
.  The HAS-
BLED score has also been validated for predicting bleeding in patients on no antithrombotic 
therapy or aspirin, as well as on OAC, whether VKA or non-VKA types of anticoagulation, as 
well as atrial fibrillation and non-atrial fibrillation patients.  Thus, the HAS-BLED score would 
be applicable thoughout the patient pathway, which is an important consideration given 
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that risk assessment is not a static process and patient’s risk evolves over time.  The ORBIT 
score has only been validated in anticoagulated patients. 
 
Limitations 
These results are based on a post-hoc analysis of the AMADEUS trial, and should be 
interpreted as hypothesis-generating. The AMADEUS trial population was perhaps at 
relatively low risk for bleeding events when compared with atrial fibrillation patients in 
clinical practice, since patients with a history of major bleeding events were excluded from 
this trial. 
 
In conclusion, the HAS-BLED, ATRIA and ORBIT bleeding risk scores all demonstrated modest 
performance in predicting bleeding outcomes, although the HAS-BLED score performed 
significantly better than the ORBIT and ATRIA scores, in predicting clinically relevant 
bleeding.  TTR was strongly correlated with clinically relevant bleeding events in patients 
assessed by the ATRIA and ORBIT scores, even amongst those categorised as ‘low risk’.  
Significant improvements in both ATRIA and ORBIT score prediction performances were 
achieved by considering quality of anticoagulation control, by adding TTR to both scores.   
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Table 1: Demographic and clinical characteristics of patients on warfarin (n=2293) 
Age, years 71 (64-77) 
Males 1501 (65.5) 
Body Mass Index 28 (25.3-31.2) 
Type of AF 
 
- Paroxysmal 813 (35.5) 
- Persistent 214 (9.3) 
- Permanent 1258 (54.9) 
Hypertension 1764 (76.9) 
Heart Failure 543 (23.7) 
Diabetes Mellitus 450 (19.6) 
Coronary Artery Disease 718 (31.3) 
Stroke/TIA 575 (25.1) 
Creatinine clearance mls/min 71.4 (55.2-91.7) 
Time in therapeutic range (TTR) 58 (45-70) 
Use of Aspirin 379 (16.5) 
Use of NSAID 123 (5.4) 
CHA2DS2-VASc score (IQR) 3 (2-4) 
1 (%) 180 (7.8) 
2 (%) 481 (21) 
3 (%) 567 (24.7) 
4 (%) 501 (21.8) 
5 (%) 321 (14) 
6 (%) 160 (7) 
7 (%) 68 (3) 
8 (%) 14 (0.6) 
9 (%) 1 (0.0) 
HAS-BLED score 2 (1-2) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Low: <3 1739 (75.9) 
High: ≥3 553 (24.1) 
ATRIA score 1 (1-3) 
Low: 0-3 2042 (90.1) 
Intermediate: 4 98 (4.3) 
High: ≥5 127 (5.6) 
ORBIT score 1 (0-1) 
Low: 0-2 2106 (92.9) 
Intermediate: 3 129 (5.7) 
High: ≥4 32 (1.4) 
 
AF= Atrial Fibrillation; IQR= interquartile range; NSAIDS= Non-Steroidal Anti-Inflammatory 
Drugs; TIA= transient ischemic attack; TTR= time in therapeutic range   
CHA2DS2-VASc score= Congestive heart failure, Hypertension, Age≥ 75 years (2 points), 
Diabetes mellitus, previous Stroke/transient ischemic attack/thromboembolism (2 points), 
Vascular disease, Age 65-74 years, and female gender 
HAS-BLED score= Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, 
Labile international normalized ratio (INR), Elderly (age≥65 years), drugs or alcohol 
concomitant 
ATRIA score= anemia (hemoglobin <13 g/dl in men and <12 g/dl in women) (3 points), 
severe renal disease (glomerular filtration rate <30 ml/min/1.73m
2
 or dialysis dependent) 
(3points), age≥75 years (2 points), prior bleeding and hypertension. 
ORBIT score=  Older age (≥ 74 years), reduced hemoglibin/Anemia [(hemoglobin <13 g/dl in 
men and <12 g/dl in women) or (hematocrit <40% for males and <36% for females) (2 
points)], Bleeding history (2 points), Insufficient kidney function [glomerular filtration rate 
<60 ml/min/1.73m
2
], Treatment with Antiplatelet. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
Table 2: Cox regression analysis of HAS-BLED, ATRIA and ORBIT score for 
bleeding outcomes  
 
HR; hazard ratio, CI; Confidence Interval
 Any clinically 
relevant bleeding 
 Major bleeding  
 HR (95%CI) P value HR (95%CI) P value 
HAS-BLED  
high score (≥3) 
1.85 (1.43-2.40) <0.001 2.40 (1.28-4.52) 0.007 
ATRIA  
Inter/high score 
(≥4) 
1.13 (0.76-1.69) 0.54 2.40 (1.10-5.22) 0.03 
ORBIT  
Inter/high score 
(≥3) 
1.23 (0.79-1.93) 0.36 2.93 (1.29-6.64) 0.01 
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Table 3: Comparison of AUCs for HAS-BLED, ATRIA and ORBIT scores 
 
 
 
 
 
 
 
 
AUC; area under the curve, CI; confidence interval 
 
 Any clinically 
relevant bleeding 
  Major bleeding   
 AUC difference 
(95%CI) 
Z score P value AUC difference 
(95%CI) 
Z score P value 
Comparison       
HAS-BLED vs. 
ATRIA 
0.09 (0.03-0.15) 3.11 0.002 0.04 (-0.06-0.14) 0.80 0.42 
HAS-BLED vs. 
ORBIT 
0.07 (0.03-0.12) 3.39 0.001 0.04 (-0.06-0.14) 0.74 0.46 
ATRIA vs. 
ORBIT 
0.02 (-0.05-0.08) 0.44 0.66 0.002 (-0.05-0.05) 0.07 0.94 
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scores 
 
AUC; Area under the curve, NRI; Net reclassification improvement, IDI; 
Integrated discriminant improvement 
 
 
 ATRIA+TTR vs ATRIA    ORBIT+TTR vs ORBIT 
 Any clinically relevant 
bleeding 
P value Major 
bleeding 
P value Any clinically relevant 
bleeding 
AUC 
difference 
0.064 0.001 0.039 0.251 0.054 
NRI 0.260 <0.001 0.348 0.02 0.260 
IDI 0.0066 <0.001 0.002 0.065 0.0065 
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and ORBIT scores 
a) Any clinically relevant bleeding 
 
b) Major bleeding 
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Figure 2: AUC (area under the curve) for bleeding endpoints with the 3 bleeding risk scores   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Any clinically 
relevant 
bleeding 
   Major 
bleeding 
   
AUC 
Analysis 
AUC 95%CI SE P value AUC 95%CI SE P value 
HAS-BLED 0.59 0.56-0.63 0.02 <0.001 0.65 0.56-0.73 0.04 0.002 
ATRIA 0.50 0.46-0.53 0.02 0.80 0.61 0.51-0.70 0.05 0.02 
ORBIT 0.52 0.48-0.56 0.02 0.30 0.61 0.51-0.70 0.05 0.02 
a) Any clinically relevant bleeding b) Major bleeding 
HAS-BLED 
ATRIA 
ORBIT 
AUC; area under the curve, CI; confidence interval, SE; standard error 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure 3   Any clinically relevant bleeding in relation to tertiles of Time to 
Therapeutic Range (TTR) and TTR as a continuous variable, by ORBIT and 
ATRIA scores 
(a) TTR by tertiles of TTR 
 
 
(b) TTR as a continuous variable, vs ORBIT score 
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(c) TTR as a continuous variable, vs ATRIA score 
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Clinical significance 
  
• In this study, the HAS-BLED score performed significantly better than the 
ATRIA and ORBIT scores, in predicting clinically relevant bleeding. 
 
• Quality of anticoagulation control (as reflected by time in therapeutic 
range,TTR) was strongly correlated with clinically relevant bleeding events in 
patients assessed by both ATRIA and ORBIT scores (which do not consider 
TTR).   
 
• Improvements in both ATRIA and ORBIT score prediction performances were 
achieved by adding TTR to both scores.    
